Angiotensin receptor blockers: Focus on cardiac and renal injury

Trends in Cardiovascular Medicine

Volumn 26, Issue 3, 2016, Pages 221-228

  Arumugam, Somasundaram ^a   Sreedhar, Remya ^a   Thandavarayan, Rajarajan A ^a,b   Karuppagounder, Vengadeshprabhu ^a   Krishnamurthy, Prasanna ^b   Suzuki, Kenji ^c   Nakamura, Masahiko ^d   Watanabe, Kenichi ^a  

^a NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SCIENCES   (Japan)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^c NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^d Yamanashi Prefectural Central Hospital   (Japan)

Author keywords

Angiotensin receptor blocker; Diabetes mellitus; Heart failure; Hypertension; Renin angiotensin system

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; AZILSARTAN; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE; EPROSARTAN; FIMASARTAN; IRBESARTAN; LOSARTAN; OLMESARTAN; TELMISARTAN; VALSARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; HEART FAILURE; HEART INJURY; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; KIDNEY INJURY; MEDICATION COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; ANIMAL; CARDIAC MUSCLE; COMBINATION DRUG THERAPY; DRUG EFFECTS; DRUG INTERACTION; HEART; HEART DISEASES; KIDNEY; KIDNEY DISEASES; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN II TYPE 2 RECEPTOR BLOCKERS; ANIMALS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HEART; HEART DISEASES; HUMANS; KIDNEY; KIDNEY DISEASES; MYOCARDIUM; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RENIN-ANGIOTENSIN SYSTEM; TREATMENT OUTCOME;

EID: 84936802735     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2015.06.004     Document Type: Review

References (39)

1. Ntountaniotis D., Mali G., Grdadolnik S.G., et al. Thermal, dynamic and structural properties of drug AT1 antagonist olmesartan in lipid bilayers. Biochim Biophys Acta 2011, 1808:2995-3006.
2. Silva-Filho J.L., Souza M.C., Henriques M., et al. AT1 receptor-mediated angiotensin II activation and chemotaxis of T lymphocytes. Mol Immunol 2011, 48:1835-1843.
3. Arumugam S., Thandavarayan R.A., Palaniyandi S.S., et al. Candesartan cilexetil protects from cardiac myosin induced cardiotoxicity via reduction of endoplasmic reticulum stress and apoptosis in rats: involvement of ACE2-Ang (1-7)-mas axis. Toxicology 2012, 291:139-145.
4. Sukumaran V., Veeraveedu P.T., Gurusamy N., et al. Olmesartan attenuates the development of heart failure after experimental autoimmune myocarditis in rats through the modulation of ANG 1-7 mas receptor. Mol Cell Endocrinol 2012, 351:208-219.
5. Verdecchia P., Angeli F., Gentile G., Mazzotta G., Reboldi G. Telmisartan for the reduction of cardiovascular morbidity and mortality. Expert Rev Clin Pharmacol 2011, 4:151-161.
6. Chujo D., Yagi K., Asano A., et al. Telmisartan treatment decreases visceral fat accumulation and improves serum levels of adiponectin and vascular inflammation markers in Japanese hypertensive patients. Hypertens Res 2007, 30:1205-1210.
7. Takagi H., Mizuno Y., Iwata K., Goto S.N., Umemoto T. Blood pressure-independent effects of telmisartan on regression of left ventricular mass: a meta-analysis and meta-regression of randomized controlled trials. Int J Cardiol 2013, 165:564-567.
8. Utsumi K., Yasuda F., Watanabe Y., et al. Effects of olmesartan and imidapril on the plasma adiponectin, P-selectin, and MDA-LDL levels of diabetic nephropathy patients. Clin Chim Acta 2012, 413:348-349.
9. Catala-Lopez F., Martin-Serrano G., Macia M.A., Montero D. Olmesartan for the prevention or delay of diabetic nephropathy: some considerations. Rev Esp Cardiol (Engl Ed) 2012, 65:678-679. [author reply 9-80].
10. Hirohata A., Yamamoto K., Miyoshi T., et al. Four-year clinical outcomes of the OLIVUS-Ex (impact of Olmesartan on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) extension trial. Atherosclerosis 2012, 220:134-138.
11. Bang C.N., Greve A.M., Kober L., et al. Renin-angiotensin system inhibition is not associated with increased sudden cardiac death, cardiovascular mortality or all-cause mortality in patients with aortic stenosis. Int J Cardiol 2014, 175:492-498.
12. Dahl J.S., Videbaek L., Poulsen M.K., et al. Prevention of atrial fibrillation in patients with aortic valve stenosis with candesartan treatment after aortic valve replacement. Int J Cardiol 2013, 165:242-246.
13. Wang H.W., Mizuta M., Saitoh Y., Noma K., Ueno H., Nakazato M. Glucagon-like peptide-1 and candesartan additively improve glucolipotoxicity in pancreatic beta-cells. Metabolism 2011, 60:1081-1089.
14. Alfarano C., Suffredini S., Fantappie O., et al. The effect of losartan treatment on the response of diabetic cardiomyocytes to ATP depletion. Pharmacol Res 2011, 63:225-232.
15. McLoughlin D., McGuinness J., Byrne J., et al. Pravastatin reduces Marfan aortic dilation. Circulation 2011, 124:S168-S173.
16. Motta M., Russo C., Vacante M., et al. Losartan vs. amlodipine treatment in elderly oncologic hypertensive patients: a randomized clinical trial. Arch Gerontol Geriatr 2011, 53:60-63.
17. Parlak A., Iyisoy A., Aydogan U., Cakir E., Saglam K. The effect of valsartan and nebivolol treatment on ADMA and pentraxin-3 levels in hypertensive patients. Med Hypotheses 2012, 79:294-298.
18. Lins R., Coen N., Aerts A., et al. Modelling of blood pressure and total cardiovascular risk outcomes after second-line valsartan therapy: the BSCORE study. Arch Cardiovasc Dis 2011, 104:428-434.
19. Tang L., Yi R., Yang B., Li H., Chen H., Liu Z. Valsartan inhibited HIF-1alpha pathway and attenuated renal interstitial fibrosis in streptozotocin-diabetic rats. Diabetes Res Clin Pract 2012, 97:125-131.
20. Cheng C.I., Hsiao C.C., Wu S.C., et al. Valsartan impairs angiogenesis of mesenchymal stem cells through Akt pathway. Int J Cardiol 2013, 167:2765-2774.
21. Doehner W., Todorovic J., Kennecke C., et al. Improved insulin sensitivity by the angiotensin receptor antagonist irbesartan in patients with systolic heart failure: a randomized double-blinded placebo-controlled study. Int J Cardiol 2012, 161:137-142.
22. Matsui T., Nishino Y., Maeda S., Takeuchi M., Yamagishi S. Irbesartan inhibits advanced glycation end product (AGE)-induced up-regulation of vascular cell adhesion molecule-1 (VCAM-1) mRNA levels in glomerular endothelial cells. Microvasc Res 2011, 81:269-273.
23. Ojima M., Igata H., Tanaka M., et al. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J Pharmacol Exp Ther 2011, 336:801-808.
24. Perry C.M. Azilsartan medoxomil: a review of its use in hypertension. Clin Drug Investig 2012, 32:621-639.
25. Lee J.Y., Lee C.W., Kim W.J., et al. Antiatherosclerotic effects of the novel angiotensin receptor antagonist Fimasartan on plaque progression and stability in a rabbit model: a double-blind placebo-controlled trial. J Cardiovasc Pharmacol 2013, 62:229-236.
26. Han J., Park S.J., Thu V.T., et al. Effects of the novel angiotensin II receptor type I antagonist, fimasartan on myocardial ischemia/reperfusion injury. Int J Cardiol 2013, 168:2851-2859.
27. Lee H.Y., Hong B.K., Chung W.J., et al. Phase IV, 8-week, multicenter, randomized, active treatment-controlled, parallel group, efficacy, and tolerability study of high-dose candesartan cilexetil combined with hydrochlorothiazide in Korean adults with stage II hypertension. Clin Ther 2011, 33:1043-1056.
28. Gu N., Kim B.H., Lim K.S., et al. The effect of fimasartan, an angiotensin receptor type 1 blocker, on the pharmacokinetics and pharmacodynamics of warfarin in healthy Korean male volunteers: a one-sequence, two-period crossover clinical trial. Clin Ther 2012, 34:1592-1600.
29. Robins G.W., Scott L.J. Eprosartan: a review of its use in the management of hypertension. Drugs 2005, 65:2355-2377.
30. Kaliuzhin V.V., Sibireva O.F., Urazova O.I., et al. Effect of eprosartan on the hemostatic system in patients with chronic kidney disease associated with hereditary thrombophilia. Ter Arkh 2013, 85:77-81.
31. Hanon O, Lee YS, Pathak A, on behalf of the OPG. Association between eprosartan-based hypertension therapy and improvement in cognitive function score: long-term follow-up from the OSCAR observational study. J Renin Angiotensin Aldosterone Syst 2013. 10.1177/1470320313491795.
32. Ohlstein E.H., Brooks D.P., Feuerstein G.Z., Ruffolo R.R. Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade. Pharmacology 1997, 55:244-251.
33. Simons W.R. Comparative cost effectiveness of angiotensin II receptor blockers in a US managed care setting: olmesartan medoxomil compared with losartan, valsartan, and irbesartan. Pharmacoeconomics 2003, 21:61-74.
34. Kusumoto K., Igata H., Ojima M., et al. Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models. Eur J Pharmacol 2011, 669:84-93.
35. Kajiya T., Ho C., Wang J., Vilardi R., Kurtz T.W. Molecular and cellular effects of azilsartan: a new generation angiotensin II receptor blocker. J Hypertens 2011, 29:2476-2483.
36. Baker W.L., Nigro S.C., White W.B. Efficacy of azilsartan medoxomil with chlorthalidone in hypertension. Expert Rev Cardiovasc Ther 2014, 12:791-798.
37. Epstein B.J., Shah N.K., Borja-Hart N.L. Management of hypertension with fixed-dose triple-combination treatments. Ther Adv Cardiovasc Dis 2013, 7:246-259.
38. Ohsawa M., Tamura K., Kanaoka T., et al. Addition of aliskiren to Angiotensin receptor blocker improves ambulatory blood pressure profile and cardiorenal function better than addition of benazepril in chronic kidney disease. Int J Mol Sci 2013, 14:15361-15375.
39. Michel M.C., Foster C., Brunner H.R., Liu L. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol Rev 2013, 65:809-848.